文献速递免疫规划

编码细菌抗原的自扩增mRNA疫苗诱导的免疫原性与保护效力

Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens.
PubMed 文献 · Vaccine · 2016-12-07

该研究基于自扩增mRNA(SAM)平台,构建表达A群链球菌双突变链球菌溶血素O(SLOdm)和B群链球菌菌毛2a骨架蛋白(BP-2a)的SAM疫苗。小鼠免疫后产生大量全功能血清抗体,抗体应答在A群和B群链球菌感染小鼠模型中提供一致保护;加入真核分泌信号或重组蛋白加强可提高特异性抗体水平和保护力。

要点

  • SAM疫苗可成功表达细菌抗原SLOdm和BP-2a。
  • 免疫小鼠产生大量全功能血清抗体。
  • 抗体应答在GAS和GBS感染模型中提供一致保护。

核心结论

  • 结果支持将SAM疫苗作为广谱病毒和细菌病原体潜在解决方案的概念。

研究设计与样本

  • 研究评估表达A群链球菌(GAS)和B群链球菌(GBS)抗原的SAM疫苗的免疫原性和效力,以细菌病原体为模型。

主要发现

  • 两种原型细菌抗原SLOdm和BP-2a由SAM载体成功表达。
  • 免疫小鼠产生显著量的全功能血清抗体。
  • SAM疫苗产生的抗体应答在GAS和GBS感染小鼠模型中提供一致保护。
  • 加入真核分泌信号或用重组蛋白加强导致更高的特异性抗体水平和保护。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nucleic acid vaccines represent an attractive approach to vaccination, combining the positive attributes of both viral vectors and live-attenuated vaccines, without the inherent limitations of each technology. We have developed a novel technology, the Self-Amplifying mRNA (SAM) platform, which is based on the synthesis of self-amplifying mRNA formulated and delivered as a vaccine. SAM vaccines have been shown to stimulate robust innate and adaptive immune responses in small animals and non-human primates against a variety of viral antigens, thus representing a safe and versatile tool against viral infections. To assess whether the SAM technology could be used for a broader range of targets, we investigated the immunogenicity and efficacy of SAM vaccines expressing antigens from Group A (GAS) and Group B (GBS) Streptococci, as models of bacterial pathogens. Two prototype bacterial antigens (the double-mutated GAS Streptolysin-O (SLOdm) and the GBS pilus 2a backbone protein (BP-2a)) were successfully expressed by SAM vectors. Mice immunized with both vaccines produced significant amounts of fully functional serum antibodies. The antibody responses generated by SAM vaccines were capable of conferring consistent protection in murine models of GAS and GBS infections. Inclusion of a eukaryotic secretion signal or boosting with the recombinant protein resulted in higher specific-antibody levels and protection. Our results support the concept of using SAM vaccines as potential solution for a wide range of both viral and bacterial pathogens, due to the versatility of the manufacturing processes and the broad spectrum of elicited protective immune response.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Maruggi G, Chiarot E, Giovani C, et al. Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens. Vaccine. 2016. PMID: 27939014. doi:10.1016/j.vaccine.2016.11.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。